 LEXINGTON, Mass., Nov. 4, 2020 PRNewswire -- Curis, Inc. NASDAQ: CRIS, a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that three abstracts for CA-4948, a small molecule IRAK4 inhibitor, have been accepted for... 